European Equities Move Lower Friday, Set to End Week in Negative Territory
10:59 AM EST, 01/27/2023 (MT Newswires) -- European equities were trading lower Friday, poised to end the week in negative territory, as American depositary receipts of European stocks were down 0.64%
Piper Says No Change to Positive Argenx Outlook Despite 'Puzzling' PDUFA Pushout
JMP Securities Keeps Their Buy Rating on Argenx Se (ARGX)
Sector Update: Health Care Stocks Flat to Lower Premarket Friday
09:08 AM EST, 01/27/2023 (MT Newswires) -- Health care stocks were flat to lower premarket Friday. The Health Care Select Sector SPDR Fund (XLV) was 0.1% lower and the iShares Biotechnology ETF (IBB)
Argenx Stock Dips as FDA Extends Review Period for Subcutaneous Efgartigimod
Argenx Announces FDA Extension of Efgartigimod BLA Review
Argenx Says US FDA Lenghtens Review for Investigational Treatment of Generalized Myasthenia Gravis
04:14 AM EST, 01/27/2023 (MT Newswires) -- Argenx (ARGX) said Friday that the US Food and Drug Administration has extended the review of a biologics license application for subcutaneous efgartigimod f
Argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023 Amsterdam, the Netherlands — argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that
Cowen Adjusts Price Target on Argenx to $458 From $441, Maintains Outperform Rating
10:21 AM EST, 01/25/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
ArGEN-X Price Target Raised to $458.00/Share From $441.00 by Cowen & Co.
Loading...
No Stock Yet